Carbon Monoxide–Bound Red Blood Cells Protect Red Blood Cell Transfusion-Induced Hepatic Cytochrome P450 Impairment in Hemorrhagic-Shock Rats

2012 ◽  
Vol 41 (1) ◽  
pp. 141-148 ◽  
Author(s):  
Shigeru Ogaki ◽  
Kazuaki Taguchi ◽  
Hiroshi Watanabe ◽  
Masaki Otagiri ◽  
Toru Maruyama
Keyword(s):  
Carbon Monoxide ◽  
Cytochrome P450 ◽  
Blood Cell ◽  
Hemorrhagic Shock ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Red Blood Cell Transfusion ◽  
Hepatic Cytochrome

scholarly journals Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion

Blood ◽  
2019 ◽  
Vol 134 (13) ◽  
pp. 1003-1013 ◽  
Author(s):  
Nareg H. Roubinian ◽  
Colleen Plimier ◽  
Jennifer P. Woo ◽  
Catherine Lee ◽  
Roberta Bruhn ◽  
...  
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Red Blood Cell Transfusion

Abstract This study furnishes evidence that both confirms and refutes a long-standing maxim that a one-unit transfusion of red blood cells should yield a posttransfusion hemoglobin increment of 1 g/dL.

scholarly journals Preoperative embolization of the splenic artery in patients that underwent splenectomy for immune thrombocytopenic purpura

2007 ◽  
Vol 22 (6) ◽  
pp. 470-473 ◽  
Author(s):  
PlínioCarlos Baú ◽  
Sílvio Adriano Cavazolla ◽  
Hamilton Petry Souza ◽  
Bernardo Garicochea
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Immune Thrombocytopenic Purpura ◽  
Blood Cells ◽  
Splenic Artery ◽  
Red Blood Cell Transfusion ◽  
Preoperative Embolization ◽  
Surgical Team ◽  
Thrombocytopenic Purpura

Transfusion of platelets, red blood cells, or both is usually necessary immediately after splenic artery ligature in patients with immune thrombocytopenic purpura who undergo splenectomy. PURPOSE: To investigate whether preoperative embolization of the splenic artery reduced the need for transfusion of platelets, red blood cells, or both. METHODS: Twenty- seven consecutive patients that underwent splenectomy for purpura between October 1999 and March 2006 performed by the same surgical team were enrolled. The first 17 patients did not undergo embolization and were compared with the next 10 patients, who composed the embolization group. RESULTS: The platelet count in the embolization group rose from a mean 7000 u/µl before to 75000 u/µl after the procedure. There was no need for platelet or red blood cell transfusion in the embolization group; in the group without preoperative embolization, 11 patients (p=0.001) required platelet transfusion and 8 (p=0.01), red blood cell transfusion. CONCLUSION: Embolization of the splenic artery before splenectomy is a safe method to avoid blood transfusions in patients with ITP.

Adequacy of Physician Documentation of Red Blood Cell Transfusion and Correlation With Assessment of Transfusion Appropriateness

2006 ◽  
Vol 130 (4) ◽  
pp. 474-479 ◽  
Author(s):  
Mark T. Friedman ◽  
Amber Ebrahim
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Assessment Process ◽  
Red Blood Cell Transfusion ◽  
Major Function ◽  
Red Blood Cell Transfusions ◽  
Enhance Efficiency ◽  
Transfusion Guidelines

Abstract Context.—A major function of the hospital transfusion service is to assess the appropriateness of blood transfusion. Inadequate documentation of transfusions may hamper this assessment process. Objective.—To correlate the level of physician documentation of transfusion with the ability to justify transfusion. Design.—Retrospective review of red blood cell transfusions in adult patients in 2 hospital facilities during 1-week audit periods of each month from April 2001 to March 2003. Assessment forms were used to classify the level of physician documentation of transfusions into 3 groups: adequately, intermediately, and inadequately documented. Transfusions were deemed justified or not via comparison with hospital transfusion guidelines. Results.—There were 5062 audited red blood cells transfused to 2044 adult (≥18 years) patients. Medical records from 154 patients transfused with 257 units of red blood cells during 172 transfusion events were reviewed after initial screenings of hemoglobin/hematocrit values failed to justify the transfusions. Nine percent of adequately documented, 50% of intermediately documented, and 73% of inadequately documented transfusion events could not be justified. Transfusion events with suboptimal (intermediate and inadequate) documentation accounted for 49% of all medical record–reviewed transfusion events and 62% could not be justified. The correlation between inadequate documentation and failure to justify transfusion was significant (P < .001), as was the correlation between suboptimal documentation and failure to justify transfusion (P = .03). Conclusions.—There is a significant correlation between suboptimal documentation and failure to justify transfusions. Educating clinicians to improve documentation along with appropriate indications for transfusions may enhance efficiency of blood utilization assessment and lead to reduced rates of unjustifiable transfusions.

The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada

Transfusion ◽  
2004 ◽  
Vol 44 (10) ◽  
pp. 1479-1486 ◽  
Author(s):  
Mo Amin ◽  
Dean Fergusson ◽  
Kumanan Wilson ◽  
Alan Tinmouth ◽  
Ashique Aziz ◽  
...  
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Unit Cost ◽  
Red Blood Cell Transfusion

scholarly journals Red blood cells transfusions in oncological patients treated with radio- and chemoterapy

2011 ◽  
Vol 68 (1) ◽  
pp. 28-34
Author(s):  
Ana Antic ◽  
Zoran Stanojkovic
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Red Blood Cell Transfusion ◽  
Hematological Parameter ◽  
Malignant Diseases ◽  
Adequate Treatment ◽  
Oncological Patients ◽  
Red Blood Cell Transfusions

Background/Aim. Anemia is one of the most frequent hematology disorders in patients with malignant diseases. It has a great influence on reduction of the quality of life, so it requires early diagnosis and an adequate treatment. The aim of this study was to present and analyze the treatment of anemia using red blood cell transfusions in patients with malignancies, to analyze adequate use of red blood cell transfusions according to hemoglobin concentration, and also the influence of the treatment of malignant disease on the level of anemia and use of red blood cells transfusion. Methods. This retrospective analysis included the data on the use of red blood cells in Oncological Clinic of Clinical Center Nis in a period from the 1st January 2008 to the 31st December 2008. Results. None of the patients received the whole blood. In this period, 735 patients received 1,006 units of red blood cells (red blood cell concentrate, resuspended, washed, filtered). An average use of red blood cell transfusion was 1.37 unit per oncological patient who received transfusion. The use of red blood cell units was adequate (87.60% of patients received transfusion of red cells when Hgb < 80 g/L). During radio- and chemotherapy we noticed a decrease of hematological parameter values. The patients of the experimental group were dependant on red blood cells transfusion. Statistically, a significant decrease of hemoglobin level was observed in patients treated only with radiotherapy who are the greatest consumers of red blood cells. Two patients were registered who more likely to have febrile nonhemolytic transfusion reactions. Posttransfusion alloimmunization occurred in 0.68% of the patients. Conclusion. The use of red blood cells in oncological patients is in compliance with the up to date tendencies and recommendations published in clinical guidelines. For the purpose of efficient transfusion support in patients with malignant diseases, we have to follow the newest knowledge and attitudes about clinical use of blood products.

Packed Red Blood Cell Transfusion in the Intensive Care Unit: Limitations and Consequences

2007 ◽  
Vol 16 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Suzanne Gould ◽  
Mary Jo Cimino ◽  
David R. Gerber
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Critically Ill ◽  
Red Blood Cell ◽  
Critically Ill Patients ◽  
Blood Cells ◽  
Case Series ◽  
Red Blood Cell Transfusion ◽  
Packed Red Blood Cells ◽  
Pubmed Database

• Objective To review the literature on the limitations and consequences of packed red blood cell transfusions, with particular attention to critically ill patients. • Methods The PubMed database of the National Library of Medicine was searched to find published articles on the indications, clinical utility, limitations, and consequences of red blood cell transfusion, especially in critically ill patients. • Results Several dozen papers were reviewed, including case series, meta-analyses, and retrospective and prospective studies evaluating the physiological effects, clinical efficacy, and consequences and complications of transfusion of packed red blood cells. Most available data indicate that packed red blood cells have a very limited ability to augment oxygen delivery to tissues. In addition, the overwhelming preponderance of data accumulated in the past decade indicate that patients receiving such transfusions have significantly poorer outcomes than do patients not receiving such transfusions, as measured by a variety of parameters including, but not limited to, death and infection. • Conclusions According to the available data, transfusion of packed red blood cells should be reserved only for situations in which clear physiological indicators for transfusion are present.

Unsuccessful Treatment with Lenalidomide in a Diamond-Blackfan Anemia Patient.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4219-4219
Author(s):  
Peter Joosten ◽  
Mels Hoogendoorn ◽  
Huib Storm ◽  
Robby Kibbelaar
Keyword(s):  
Blood Cell ◽  
Red Blood Cells ◽  
Ribosomal Protein ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Ribosomal Proteins ◽  
Red Blood Cell Transfusion ◽  
Red Cell ◽  
Diamond Blackfan Anemia ◽  
Red Cell Aplasia

Abstract Abstract 4219 Background Diamond-Blackfan Anemia (DBA) is an autosomal dominant inherited bone marrow failure syndrome due to a defect in the ribosomal protein (RP) synthesis. Diagnostic criteria consist of presentation of anemia before birth with near normal or slightly decreased neutrophil counts, variable platelet counts, reticulocytopenia, macrocytosis, and normal marrow cellularity with a paucity of red cell precursors (Diamond et al 1976). Patient characteristics In 2002 a 34 year old man was presented with a hemoglobin (Hb) level of 2.4 mmol/l, a MCV of 117 fl, no reticulocytes and a normal leukocyte and platelet count. Except shortness of breath he had no other complaints. He did not use any medication. On physical examination there was only a short stature. Marrow cytology showed 20% erythropoesis with some dyserythropoesis. Marrow histology and cytogenetic were normal. A recent parvovirus infection was excluded. His medical history started in 1968 at the age of five weeks. A DBA was diagnosed and treated successfully with corticosteroids. There was a relapse at the age of 3 with again a good response on corticosteroids. In 2002 he was initially treated with 6 units of red blood cells, resulting in a rise of the Hb to 6.4 mmol/l. After five months he had a Hb of 3.8 mmol/l, a normal MCV and 50.109/l reticulocytes. Kidney and adrenal function were normal, there was no hypogonadism and no splenomegaly. Hb electrophoresis showed an elevated HbF of 6.4%. By exclusion of other causes of anemia, it was concluded that the anemia had to be considered as a relapse DBA. Corticosteroids (1 mg/kg) for 6 months did not show any improvement. Cyclosporine 100 mg two times a day raised the Hb above 8 mmol/l from November 2003 till May 2004. While on cyclosporine he relapsed again and became red blood cell transfusion dependent from February 2006. A search for a HLA identical donor at that time was unsuccessful. ATG, cyclosporine and corticosteroids did not diminish the need for red blood cell transfusion. In 2007 the RPS19 (ribosomal protein S19) mutation was demonstrated in this patient, which definitively confirmed the diagnosis made 35 years ago. In 2008, still red blood cell transfusion dependent, treatment with lenalidomide 10 mg/day for 21 days during each 28 days was initiated. Treatment considerations All mutated genes in DBA cause a decreased synthesis of ribosomal proteins. As a consequence erythroid progenitors and precursors are highly sensitive to apoptosis (Perdahl et al 1994). One of the mechanisms is activation of p53 (Danilova et al 2008). Both the 5q- syndrome and DBA show haploinsufficiency for closely related ribosomal proteins RPS-19 and RPS-14. It is assumed that the pathophysiology of the 5q- syndrome and DBA are the same (Ebert et al 2007). Because lenalidomide is effective in patients with the 5q- syndrome, lenalidomide was considered as treatment option in DBA at the Annual DBA International Consensus Conferences in 2008 and 2009. Results Due to severe pancytopenia, lenalidomide was stopped after 5 weeks. During the next 6 months a slow recovery of white blood cells and platelets was observed. Before and 3 months after the start of the lenalidomide treatment marrow cytology, histology and cytogenetics were done. Both times there was a red cell aplasia, no signs of myelodysplasia and no cytogenetic abnormalities. Rechallenge with lenalidomide in a dose of 10 mg each fourth day resulted again in a pancytopenia in 6 weeks time. Each 3 weeks 3 units of red blood cells are necessary ever since. Discussion and Conclusion Treatment of DBA with lenalidomide in this patient was unsuccessful and resulted in a temporarily and severe neutropenia and thrombocytopenia. These adverse effects are also documented in 62% of the 5q- syndrome patients treated with 10 mg Lenalidomide. Moreover, in retrospect, we doubt if lenalidomide can be effective when red cell aplasia is already present as a late complication of DBA. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document